Compare MATH & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | CGTX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 158.8M |
| IPO Year | N/A | 2021 |
| Metric | MATH | CGTX |
|---|---|---|
| Price | $2.86 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 108.0K | ★ 938.3K |
| Earning Date | 12-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.37 | ★ N/A |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $0.99 | $0.22 |
| 52 Week High | $4.17 | $3.83 |
| Indicator | MATH | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 51.98 |
| Support Level | $2.84 | $1.69 |
| Resistance Level | $3.12 | $1.77 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 52.17 | 74.44 |
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.